As blocking TLR9 signaling in diseased mice could reverse NASH by improving steatohepatitis, fibrosis, and insulin resistance,43 it serves as a promising target for therapeutic intervention. Here, TLR9 is linked to metabolic dysfunction-associated steatohepatitis.